Randi Hernandez

Editor https://www.cancertherapyadvisor.com

Randi Hernandez is the oncology editor for Cancer Therapy Advisor. Randi has extensive experience in health care reporting and a particular interest in how medications shape the lives of patients and how treatments evolve, tracking them from scientific theory to clinical development, manufacturing stages, market release, and postmarketing studies. Prior to joining Haymarket, Randi held editing and/or writing roles at Pharmacy Times and Specialty Pharmacy Times, BioPharm International and Pharmaceutical Technology, Genetic Engineering and Biotechnology News (GEN), and BioPharma Dive.

All articles by Randi Hernandez

General Oncology

Researchers Reveal Racial Disparities in Access to Remdesivir for Patients With Cancer and COVID-19

Randi Hernandez

July 24, 2020

Black patients were half as likely to receive remdesivir as White patients, according to researchers from the CCC19.

Targeted and immunotherapies appear to be opening a new frontier in the management of elderly patien

ASCO 2020 Lung Cancer In-Depth

Researchers Present Evidence in Support of Broad Next-Generation Sequencing in Advanced Nonsquamous NSCLC

Randi Hernandez

June 12, 2020

Though they are costly, broad genetic assays that look for many gene mutations at once may confer more value overall than a one-off testing approach for patients with nsNSCLC.

Dr Isabel Cunningham discusses some of the important studies presented at the 2016 ASH meeting.

ASCO 2020

Less Than 50% of Patients With Cancer Received NCCN-Concordant Care in California From 2004 to 2016

Randi Hernandez

May 31, 2020

Whether a patient received NCCN guideline-concordant care seemed to depend most heavily on race and insurance status.

It may be time for clinicians to re-evaluate the use of anagrelide in patients with high-risk ET.

ASCO 2020

Approximately 30% of Anticancer Trials from 2006 to 2015 Reported Changes in Clinical Benefit Scores From Initial Approval

Randi Hernandez

May 30, 2020

Clinical benefit scores of many anticancer medications approved during the study period seemed to improve at data follow-up.

General Oncology

Dr Melvin LK Chua on Cancer Care During the COVID-19 Pandemic

Randi Hernandez

April 28, 2020

The management of patients with cancer during a pandemic should be steered by evidence, as opposed to guidelines from individual institutions or consensus agreements between physicians.

Patients with locally advanced or metastatic renal cell carcinoma randomly assigned to receive pazop

Lung Cancer

Patients With Non-Small Cell Lung Cancer May Be at the Highest Risk for COVID-19

Randi Hernandez

March 25, 2020

The researchers noted that medical distancing for those with cancer could help prevent the spread of the virus in this highly vulnerable population.

General Oncology

Cannabis Use Skyrockets Among Older Individuals

Randi Hernandez

February 24, 2020

Cannabis use is increasing among older adults — and the increase in use has been most prevalent among those who are not chronically ill.

An astrocytoma develops from astrocytes that support nerve cells and may grow in the brain or spinal cord.1

Brain Cancer

Harnessing Key Elements of the Ebola Virus in Animal Models of Glioblastoma

Randi Hernandez

February 21, 2020

A glycoprotein in Ebola called the mucin-like domain may be of interest in the development of an oncolytic for brain cancer.

A patient undergoes cancer-related surgery.

General Oncology

Therapeutic Advancements Have Facilitated Surgery Optimization, ASCO Officials Report

Randi Hernandez

February 5, 2020

ASCO outlined advances in oncology that were the most clinically meaningful or had the biggest scientific impact from October 2018 through September 2019.

ASCO GI 2020

Older Adults Are Less Likely to Receive Second-Line Therapy for Metastatic Colorectal Cancer, Study Reports

Randi Hernandez

January 24, 2020

Even though older adults were prescribed second-line therapies less frequently than younger adults, patients had similar overall survival outcomes across age subgroups.

Next post in ASCO GI 2020